viewVentriPoint Diagnostics Ltd.

VentriPoint's VMS System used to test 500 Sarcoidosis patients in Netherlands

Ventripoint Diagnostics (CVE:VPT-OTCQB-VPTDF) CEO George Adams  joined Steve Darling from Proactive Investors Vancouver on Skype with news their VMS System was used to study patients with Sarcoidosis, an inflammatory disease that affects multiple organs in the body, including the heart.

Adams told Proactive how many patients where in the study and how the company will be using this data going forward. Adams also had an update on what the company will be doing in China in 2019.

Quick facts: VentriPoint Diagnostics Ltd.

Price: 0.11 CAD

Market: TSX-V
Market Cap: $7.67 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VentriPoint Diagnostics Ltd. named herein, including the promotion by the Company of VentriPoint Diagnostics Ltd. in any Content on the Site,...


Ventripoint Diagnostics new Director sees strong path forward updated VMS system

Ventripoint Diagnostics (CVE: VPT-OTC: VPTDF) New Director Hugh MacNaught joined Steve Darling from Proactive to discuss his new role on the board of the company. He also shares his background and what he brings to the company. MacNaught also shared details about the news VMS technology and...

1 week, 5 days ago

2 min read